Gomekli

How Does Gomekli Work?

Gomekli works by inhibiting MEK1 and MEK2 — mitogen-activated protein kinase kinases that are key regulators of the RAS-MAPK/ERK signaling pathway. In NF1, a mutation in the NF1 gene causes deficiency of neurofibromin, a protein that normally acts as a brake on the RAS signaling switch. Without this brake, the RAS-MEK-ERK pathway remains overactive, driving uncontrolled cell proliferation and neurofibroma tumor growth.

By blocking MEK1 and MEK2, mirdametinib reduces downstream ERK phosphorylation — the molecular signal that instructs cells to grow and divide. In mouse models of NF1, oral dosing with mirdametinib inhibited ERK phosphorylation and reduced neurofibroma tumor volume and proliferation, validating this approach before clinical testing.

In the pivotal ReNeu clinical trial, Gomekli produced confirmed overall response rates of 41% in adults and 52% in pediatric patients, with median best tumor volume reductions of -41% and -42% respectively. Most responses were durable, with 88% of adult responders and 90% of pediatric responders maintaining response for at least 12 months.

How Hard Is It to Find Gomekli In Stock?

Gomekli is not on the FDA's official drug shortage list as of 2026. However, because it is a specialty drug distributed through a limited network of authorized specialty pharmacies — and not available at retail pharmacies — finding it requires navigating a different process than most medications. Patients cannot simply walk into a CVS or Walgreens to fill this prescription.

The most common access barriers for Gomekli are insurance prior authorization requirements, identifying an in-network specialty pharmacy, and completing enrollment in the SpringWorks CareConnections support program. For newly approved specialty drugs, these administrative steps can delay treatment by days to weeks even when supply is technically available.

If you're struggling to find which specialty pharmacies near you can fill your Gomekli prescription, medfinder calls pharmacies on your behalf and texts you results — saving you hours of frustrating phone calls.

Who Can Prescribe Gomekli?

Gomekli is not a controlled substance and does not require a special DEA registration. Any licensed prescriber can write for Gomekli. However, because NF1 requires specialized diagnosis, imaging interpretation, and safety monitoring (including echocardiograms and ophthalmic assessments), it should be prescribed by or in consultation with providers experienced in NF1 management.

Neuro-oncologists

Pediatric hematologists/oncologists

Medical oncologists (with rare tumor or rare disease experience)

Neurologists and pediatric neurologists

Rare disease and genetics specialists at NF multidisciplinary clinics

Nurse practitioners (NPs) and physician assistants (PAs) working in oncology or rare disease settings

Telehealth follow-up is increasingly available for NF1 patients, particularly at academic NF centers. Initial evaluation typically requires in-person assessment including MRI imaging. The Children's Tumor Foundation (ctf.org) maintains a directory of NF clinics across the U.S.

Is Gomekli a Controlled Substance?

No. Gomekli (mirdametinib) is not a controlled substance and is not assigned a DEA schedule. It does not require a special DEA registration to prescribe or dispense. Any licensed healthcare provider with prescribing authority can write a prescription for Gomekli without the special restrictions that apply to controlled substances.

However, Gomekli is a restricted-distribution specialty drug available only through authorized specialty pharmacies. This distribution restriction is related to the drug's complexity and cost management — not its potential for abuse or addiction. Prescriptions can be written for 90-day supplies in some cases, and refills are possible.

Common Side Effects of Gomekli

The most common side effects of Gomekli (occurring in more than 25% of adult patients in the ReNeu trial) include:

Rash (most common; ranges from mild to severe)

Diarrhea

Nausea

Musculoskeletal pain (muscle and joint aches)

Vomiting

Fatigue

Serious Side Effects of Gomekli

Ocular toxicity: Retinal vein occlusion (2.7% of adults), retinal pigment epithelium detachment (1.3%), blurred vision (9%). Call your doctor immediately for any vision changes.

Left ventricular dysfunction: Heart pumping problems; higher risk in children. Echocardiogram required before treatment and every 3 months in the first year.

Severe skin reactions: Seek immediate care for blistering or peeling skin.

Embryo-fetal toxicity: Can cause fetal harm. Contraception required during treatment and for 6 weeks (females) or 3 months (males) after last dose.

Final Thoughts on Gomekli

Gomekli (mirdametinib) represents a major advancement in the treatment of NF1-associated plexiform neurofibromas. As the first FDA-approved therapy for both adults and children with this condition, it fills a critical gap that left adult NF1 patients without approved treatment options for decades. The ReNeu trial demonstrated robust, durable tumor shrinkage and meaningful quality-of-life improvements — outcomes that are life-changing for patients with this often-debilitating condition.

Access remains the biggest challenge for most patients in 2026. The combination of prior authorization requirements, specialty-only distribution, and high list price creates real-world barriers — even when the drug is technically available. The SpringWorks CareConnections program significantly reduces financial barriers, and enrollment should be initiated at the time of prescribing.

If you are having difficulty finding which specialty pharmacies near you can fill your Gomekli prescription, medfinder calls pharmacies on your behalf and texts you results — helping you locate your prescription without the frustrating hours on hold.